USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
17 Jan 2024 | 04:00 PM GMT

The Complete Story: Using RWE to Better Understand the Patient Experience

This session is exclusive to certain members only.
If you are interested in finding out more, please contact us.

Anchored by:

Brett Wisse
Director Commercial Operations
QUEST DIAGNOSTICS
Kelly Brassil
Senior Director, Business development
PACK HEALTH

Participants:

Brett Wisse Director Commercial OperationsQuest Diagnostics
Brett Wisse
Director Commercial OperationsQuest Diagnostics
Kelly Brassil Senior Director, Business developmentPack Health
Kelly Brassil
Senior Director, Business developmentPack Health
Annie Boucher International Director, Patient ExperienceNovartis
Annie Boucher
International Director, Patient ExperienceNovartis
Felix Lee US Digital Healthcare Medical HeadSanofi
Felix Lee
US Digital Healthcare Medical HeadSanofi
Jennie Medin Head Digital R&D, Respiratory and ImmunologyAstraZeneca
Jennie Medin
Head Digital R&D, Respiratory and ImmunologyAstraZeneca
Julie Carty Head of GrowthHLTH Community
Julie Carty
Head of GrowthHLTH Community
Jyoti Aggarw Snr. Director, Integrated Value Evidence LeadOtsuka Pharmaceutical Companies (U.S.)
Jyoti Aggarw
Snr. Director, Integrated Value Evidence LeadOtsuka Pharmaceutical Companies (U.S.)
Nikolas Karkanias VP, Medical Content and Channel SolutionsPfizer
Nikolas Karkanias
VP, Medical Content and Channel SolutionsPfizer
Tessy Huss Director of Strategy , HLTH CommunityHLTH Community
Tessy Huss
Director of Strategy , HLTH CommunityHLTH Community
Vanessa Quintero Real World Evidence OncologyBayer
Vanessa Quintero
Real World Evidence OncologyBayer

About this Meeting

The use of real-world evidence (RWE) in pharmaceutical R&D has increased significantly in recent years. RWE is defined as the clinical evidence obtained from the analysis of real-world data (RWD), including data from electronic medical records, claims databases, and patient-generated data.  

Pharmaceutical companies have become well-versed in the RWE generation to fulfill post-marketing commitments and gain a deeper understanding of how drugs fare in real-world settings. Less attention has been given to how RWE can generate insight into patient experience during phase III and beyond. 

In this roundtable discussion, organised in collaboration with Pack Health - we will explore current approaches to RWE generation strategies in pharmaceutical companies. Specifically, we will focus on: 

  • What are the challenges and opportunities for leveraging RWE in earlier stages of the R&D process? 
  • How can pharma companies effectively partner with external organizations to generate evidence? 
  • What specific type of evidence do they look for from external partners and what type of organizations are they most likely to partner with? 
  • Are lab data insights considered a priority, and if so, what types of lab data are sought and in what context? 
  • How can RWE be effectively utilized to gain an enhanced understanding of the patient experience?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.